Tempest Therapeutics (TPST) Net Cash Flow (2012 - 2025)
Tempest Therapeutics (TPST) posted Net Cash Flow of $193000.0 for Q4 2025, up 102.85% sequentially from -$6.8 million in Q3 2025, and down 97.53% YoY from $7.8 million in Q4 2024.
Tempest Therapeutics (TPST) Net Cash Flow (2012 - 2025) Analysis & Trends
Tempest Therapeutics has reported Net Cash Flow for 14 years, with the latest figure at $193000.0 in Q4 2025.
- Quarterly Net Cash Flow fell 97.53% year-over-year to $193000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$22.6 million (down 151.74% YoY) and the FY2025 annual result came in at -$22.6 million, down 151.74% from the prior year.
- Net Cash Flow grew to $193000.0 in Q4 2025 per TPST's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $41.0 million in Q2 2021 and troughed at -$11.6 million in Q4 2022.
- A 5-year average of -$533500.0 and a median of -$6.6 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow jumped 343.64% in 2023, then slumped 501.58% in 2025.
- Over 5 years, Net Cash Flow stood at -$8.0 million in 2021, then plunged by 44.13% to -$11.6 million in 2022, then surged by 343.64% to $28.2 million in 2023, then slumped by 72.31% to $7.8 million in 2024, then sank by 97.53% to $193000.0 in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $193000.0, -$6.8 million, and -$7.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | Tempest Therapeutics | 4.44 Mn | 3.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 193,000.00 |
| Dec 31, 2025 | 193,000.00 |
| Sep 30, 2025 | -6.77 Mn |
| Sep 30, 2025 | -6.77 Mn |
| Jun 30, 2025 | -7.23 Mn |
| Jun 30, 2025 | -7.23 Mn |
| Mar 31, 2025 | -8.76 Mn |
| Mar 31, 2025 | -8.76 Mn |
| Dec 31, 2024 | 7.80 Mn |
| Dec 31, 2024 | 7.80 Mn |
| Sep 30, 2024 | -8.66 Mn |
| Sep 30, 2024 | -8.66 Mn |
| Jun 30, 2024 | -1.20 Mn |
| Jun 30, 2024 | -1.20 Mn |
| Mar 31, 2024 | -6.90 Mn |
| Mar 31, 2024 | -6.90 Mn |
| Dec 31, 2023 | 28.17 Mn |
| Dec 31, 2023 | 28.17 Mn |
| Sep 30, 2023 | -6.47 Mn |
| Sep 30, 2023 | -6.47 Mn |